Domača stranAMPH • NASDAQ
add
Amphastar Pharmaceuticals Inc
45,46 $
Po zaprtju:(0,00 %)0,00
45,46 $
Konec trgovanja: 22. nov., 16:08:36 GMT -5 · USD · NASDAQ · Izjava
Prejšnji trg. dan.
44,55 $
Dnevni razpon
44,95 $ - 45,65 $
Letni razpon
36,56 $ - 65,92 $
Tržna kapitalizacija
2,20 mrd. USD
Povprečni obseg
374,44 tis.
Razm. P/E
15,13
Dividendna donosnost
-
Primarna borza
NASDAQ
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 191,21 mio. | 5,90 % |
Stroški poslovanja | 44,89 mio. | 25,66 % |
Čisti dohodek | 40,43 mio. | −17,86 % |
Čista dobičkovnost prihodkov | 21,14 | −22,45 % |
Earnings per share | 0,96 | −16,52 % |
EBITDA | 70,45 mio. | −17,41 % |
Efektivna davčna stopnja | 15,21 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 250,49 mio. | −16,47 % |
Skupna sredstva | 1,55 mrd. | 0,04 % |
Skupne obveznosti | 817,50 mio. | −13,90 % |
Celoten lastniški kapital | 727,68 mio. | — |
Shares outstanding | 48,08 mio. | — |
Razmerje P/B | 2,96 | — |
Donosnost sredstev | 9,39 % | — |
Donosnost kapitala | 10,60 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | 40,43 mio. | −17,86 % |
Denar iz dejavnosti | 59,96 mio. | −6,80 % |
Denar iz naložb | −34,59 mio. | −11,02 % |
Denar iz financiranja | −22,82 mio. | −126,34 % |
Neto sprememba denarnih sredstev | 2,50 mio. | −97,91 % |
Prost denarni tok | 25,06 mio. | −49,93 % |
Vizitka
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.
In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.
In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn. Wikipedia
Datum ustanovitve
1996
Sedež organizacije
Spletno mesto
Zaposleni
1.761
